Gene expression and hypoxia in breast cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most solid tumors and is associated with poor prognosis in several cancer types, including breast cancer. The master regulator of the hypoxic response is the Hypoxia-inducible factor 1α (HIF-1α). It is becoming clear that HIF-1α expression alone is not a reliable marker of tumor response to hypoxia, and recent studies have focused on determining gene and microRNA (miRNA) signatures for this complex process. The results of these studies are likely to pave the way towards the development of a robust hypoxia signature for breast and other cancers that will be useful for diagnosis and therapy. In this review, we outline the existing markers of hypoxia and recently identified gene and miRNA expression signatures, and discuss their potential as prognostic and predictive biomarkers. We also highlight how the hypoxia response is being targeted in the development of cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 5×
“Specifically, HIF1α can inhibit mTOR through its targets Regulated in develop ment and DNA damage responses 1 (REDD1) and BNIP3 [30,31], whereas mTOR inhibition can result in increased HIF1‐α translation, resulting in a regulatory loop [32].”
InfluentialThe impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365 · cited 1×
“HIF3α is highly expressed in thymus, cerebellum and cornea, where it acts in a dominantnegative fashion to inhibit HIF1α and HIF2α (for a review, see [9]).”
Hypoxia-inducible factor 1: master regulator of O2 homeostasis
Semenza, G. L. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80016-6 · Cited by 1,092
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 4×
“is miRNA has been validated as a HIF-1 target [77,78] and its expression levels significantly correlated with a hypoxia gene expression signature in breast cancer [47], suggesting that it is also regulated by hypoxia in vivo.”
InfluentialFasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M. C., & Martelli, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800731200 · Cited by 912
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894 · cited 2×
“In particular, mTOR is a sensor of metabolic signals that can influence cell survival and growth through changes in several signaling pathways that are involved in protein synthesis, autophagy, apoptosis and metabolism [29].”
Chan, S. Y., Zhang, Y.-Y., Hemann, C., Mahoney, C. E., Zweier, J. L., & Loscalzo, J. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.015 · Cited by 702 · cited 1×
“ISCU Iron sulfur cluster sca old homolog [68,107]”
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
Krohn, K. A., Link, J. M., & Mason, R. P. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045914 · Cited by 506
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500
MicroRNA regulation of DNA repair gene expression in hypoxic stress
Crosby, M. E., Kulshreshtha, R., Ivan, M., & Glazer, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2516 · Cited by 437 · cited 1×
“Several targets have been investigated to date (Figure 2 and Table 4) showing roles for hsa-miR-210 in cell-cycle regulation, apoptosis, iron accumulation, the production of reactive oxygen species, cell metabolism, DNA repair, tumor initiation, and the survival, migration and differentiation of endothelial cells (Fig…”
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
Winter, S. C., Buffa, F. M., Silva, P., Miller, C., Valentine, H. R., Turley, H., Shah, K. A., Cox, G. J., Corbridge, R. J., Homer, J. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3322 · Cited by 410 · cited 5×
“[47] Signature of hypoxia-related genes in HNSCC: 99 genes NKI data set: MFS HR = 2.”
InfluentialSelf-citationThe hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334 · cited 1×
“HIF1α activation has also been associated with resis tance to endocrine therapy and chemotherapy [35].”
Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.-L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010345 · Cited by 324 · cited 4×
“Several targets have been investigated to date (Figure 2 and Table 4) showing roles for hsa-miR-210 in cell-cycle regulation, apoptosis, iron accumulation, the production of reactive oxygen species, cell metabolism, DNA repair, tumor initiation, and the survival, migration and differentiation of endothelial cells (Fig…”
InfluentialSelf-citationKoh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Vleugel, M. M., Greijer, A. E., Shvarts, A., van der Groep, P., van Berkel, M., Aarbodem, Y., van Tinteren, H., Harris, A. L., van Diest, P. J., & van der Wall, E. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.019885 · Cited by 227 · cited 2×
“[21] Early BC 166 Unfavorable prognosis for HIF‐1α DFS HR = 2.”
Self-citationRapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171 · cited 2×
“It may be that, in the clinical setting, such agents will have synergy with drugs such as bevacizumab, which is thought to cause treatmentinduced hypoxia and subsequent HIF1α activation that lead to drug resistance [46].”
Li, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., & Park, J.-W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0074 · Cited by 160
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151 · cited 1×
“[94] Early BC 171 Unfavorable prognosis for HIF‐1α.”
Helczynska, K., Larsson, A.-M., Holmquist Mengelbier, L., Bridges, E., Fredlund, E., Borgquist, S., Landberg, G., Påhlman, S., & Jirström, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1135 · Cited by 136
Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., Parker, C. A., Stratford, I. J., & Williams, K. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.015743 · Cited by 125 · cited 1×
“In vitro data suggest that small molecule inhibitors of HIF1α in combination with adenovirusdelivered gene therapy might reverse the hypoxic chemoresistance of cancer cells [48].”
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., Horvat, R., Jakesz, R., & Birner, P. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9190-3 · Cited by 106 · cited 1×
“[95] LN+ early BC 119 Unfavorable prognosis for HIF‐1α OS HR = NR; P = 0.”
Jones, D. T., Trowbridge, I. S., & Harris, A. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3857 · Cited by 75 · cited 1×
“The antiHIF activity of two other novel anticancer drugs, AJM290 and AW464, has also been examined; both compounds inhibit HIF1α transcription at the CAD and DNAbinding domains, although they also inhibit HIF degradation [56].”
Self-citationJones, D. T., Pugh, C. W., Wigfield, S., Stevens, M. F. G., & Harris, A. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2380 · Cited by 48 · cited 1×
“with antisurface transferrin receptor (TFR) antibody [55].”
Self-citationResults from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.
Tibes, R., Falchook, G. S., Von Hoff, D. D., Weiss, G. J., Iyengar, T., Kurzrock, R., Pestano, L., Lowe, A. M., & Herbst, R. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3076 · Cited by 46
Marshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., Meyers, F. J., Hynes, H. E., Barlogie, B., & Eisenberger, M. (1993) · Investigational New Drugs · doi:10.1007/bf00874157 · Cited by 24 · cited 1×
“Echinomycin Quinoxaline antibiotic Inhibits HIF-1 binding to DNA Minimal evidence of efficacy in the treatment of solid tumors in phase 2 trials [99]”
Cited by
Advances in Hypoxia-Inducible Factor Biology
Choudhry, H., & Harris, A. L. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.005 · Cited by 868
Self-citationThe Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420
“Increased expression of HIF target genes in primary breast cancers is associated with increased patient mortality (17, 18).”
BackgroundHypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Self-citation
Metadata
- Authors
- Favaro, E., Lord, S., Harris, A. L., & Buffa, F. M.
- Venue
- Genome Medicine
- Published
- 2011
- Volume
- 3
- Issue
- 8
- Pages
- 55
- ISSN
- 1756-994X (ISSN-L)
- OpenAlex
- W2150589406
- Cited by
- 88
- References
- 32
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.